186 related articles for article (PubMed ID: 35960493)
1. The Influence of ABCB1 (rs1045642 and rs4148738) Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Aged 80 Years and Older with Nonvalvular Atrial Fibrillation.
Sychev D; Ostroumova O; Cherniaeva M; Shakhgildian N; Mirzaev K; Abdullaev S; Denisenko N; Sozaeva Z; Kachanova A; Gorbatenkova S; Shastina V
High Blood Press Cardiovasc Prev; 2022 Sep; 29(5):469-480. PubMed ID: 35960493
[TBL] [Abstract][Full Text] [Related]
2. Influence of
Wang Y; Chen M; Chen H; Wang F
Front Pharmacol; 2021; 12():639854. PubMed ID: 33935730
[No Abstract] [Full Text] [Related]
3. Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice.
Sychev DA; Sokolov AV; Reshetko OV; Fisenko VP; Sychev IN; Grishina EA; Bochkov PO; Shevchenko RV; Abdullaev SP; Denisenko NP; Ivashchenko DV; Sozaeva ZA; Kachanova AA
Pharmacogenet Genomics; 2022 Dec; 32(9):301-307. PubMed ID: 36256705
[TBL] [Abstract][Full Text] [Related]
4. The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation.
Wu T; Wu S; Li L; Xiang J; Wang N; Chen W; Zhang J
Hum Genomics; 2023 Jul; 17(1):59. PubMed ID: 37420302
[TBL] [Abstract][Full Text] [Related]
5. Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery.
Sychev D; Minnigulov R; Bochkov P; Ryzhikova K; Yudina I; Lychagin A; Morozova T
High Blood Press Cardiovasc Prev; 2019 Oct; 26(5):413-420. PubMed ID: 31617197
[TBL] [Abstract][Full Text] [Related]
6. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation.
Ji Q; Zhang C; Xu Q; Wang Z; Li X; Lv Q
Br J Clin Pharmacol; 2021 May; 87(5):2247-2255. PubMed ID: 33179295
[TBL] [Abstract][Full Text] [Related]
7. The impact of
Sychev DA; Levanov AN; Shelekhova TV; Bochkov PO; Denisenko NP; Ryzhikova KA; Mirzaev KB; Grishina EA; Gavrilov MA; Ramenskaya GV; Kozlov AV; Bogoslovsky T
Pharmgenomics Pers Med; 2018; 11():127-137. PubMed ID: 30100750
[TBL] [Abstract][Full Text] [Related]
8. Effect of ABCB1 Genotypes on the Pharmacokinetics and Clinical Outcomes of New Oral Anticoagulants: A Systematic Review and Meta-analysis.
Xie Q; Xiang Q; Mu G; Ma L; Chen S; Zhou S; Hu K; Zhang Z; Cui Y; Jiang J
Curr Pharm Des; 2018; 24(30):3558-3565. PubMed ID: 30338730
[TBL] [Abstract][Full Text] [Related]
9. Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease.
Sychev D; Skripka A; Ryzhikova K; Bochkov P; Shevchenko R; Krupenin P; Ivashchenko D; Kogay V; Listratov A; Krainyaya A; Gurinovich O; Sokolova A; Napalkov D; Fomin V
Drug Metab Pers Ther; 2020 Mar; 35(1):. PubMed ID: 32134727
[TBL] [Abstract][Full Text] [Related]
10. The Distribution of the Genotypes of
Abdrakhmanov A; Akilzhanova A; Shaimerdinova A; Zhalbinova M; Tuyakova G; Abildinova S; Albayev R; Ainabekova B; Chinybayeva A; Suleimen Z; Bekbossynova M
Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372371
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring.
Rytkin E; Bure IV; Bochkov PO; Akmalova KA; Mirzaev KB; Cherniaeva MS; Ostroumova OD; Smirnov VV; Grishina EA; Saribekian AG; Sychev IN; Sychev DA
Drug Metab Pers Ther; 2021 Aug; 37(1):41-46. PubMed ID: 35385896
[TBL] [Abstract][Full Text] [Related]
12. Toward Genetic Testing of Rivaroxaban? Insights from a Systematic Review on the Role of Genetic Polymorphism in Rivaroxaban Therapy.
Ma Y; Song Z; Li X; Jiang D; Zhao R; Yi Z
Clin Pharmacokinet; 2024 Mar; 63(3):279-291. PubMed ID: 38460105
[TBL] [Abstract][Full Text] [Related]
13. The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation.
Zhu Z; Qian C; Su C; Tao H; Mao J; Guo Z; Zhu X; Pan J
BMC Cardiovasc Disord; 2022 Nov; 22(1):481. PubMed ID: 36368930
[TBL] [Abstract][Full Text] [Related]
14. Common P-glycoprotein (
Slišković AM; Palić J; Božina T; Ganoci L; Vrkić Kirhmajer M; Trkulja V; Bulum J; Šimičević L
Biochem Med (Zagreb); 2024 Jun; 34(2):020703. PubMed ID: 38665866
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring.
Rytkin E; Bure IV; Bochkov PO; Akmalova KA; Mirzaev KB; Cherniaeva MS; Ostroumova OD; Smirnov VV; Grishina EA; Saribekian AG; Sychev IN; Sychev DA
Drug Metab Pers Ther; 2021 Aug; ():. PubMed ID: 34390638
[TBL] [Abstract][Full Text] [Related]
16. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin.
Gouin-Thibault I; Delavenne X; Blanchard A; Siguret V; Salem JE; Narjoz C; Gaussem P; Beaune P; Funck-Brentano C; Azizi M; Mismetti P; Loriot MA
J Thromb Haemost; 2017 Feb; 15(2):273-283. PubMed ID: 27893182
[TBL] [Abstract][Full Text] [Related]
17. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.
Nakagawa J; Kinjo T; Iizuka M; Ueno K; Tomita H; Niioka T
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):297-304. PubMed ID: 32920985
[TBL] [Abstract][Full Text] [Related]
18. Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial.
Pan Y; Chen W; Wang Y; Li H; Johnston SC; Simon T; Zhao X; Liu L; Wang D; Meng X; Wang Y;
JAMA Neurol; 2019 May; 76(5):552-560. PubMed ID: 30742211
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1.
Liang X; Shi H; Bi K; Feng S; Chen S; Zhao W; Huang X
Sci Rep; 2024 Jan; 14(1):2577. PubMed ID: 38297024
[TBL] [Abstract][Full Text] [Related]
20. Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation.
Sychev D; Mirzaev K; Cherniaeva M; Kulikova M; Bochkov P; Shevchenko R; Gorbatenkova S; Golovina O; Ostroumova O; Bahteeva D; Rytkin E
Drug Metab Pers Ther; 2020 Sep; 35(3):. PubMed ID: 32975202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
